Figure 5.
Figure 5. Inhibition of signaling pathways by tyrosine kinase inhibitors in Ba/F3 cells. (A) Ba/F3 cells were treated with dasatinib or ruxolitinib for 1 hour, harvested, and assessed for phosphorylation of STAT5 and CRKL. Heat map indicates mean fluorescent intensity and was generated using Cytobank. (B) Phosphorylation of extracellular signal-regulated kinase 1/2 in Ba/F3-ETV6-NTRK3 cells at basal levels or after treatment with crizotinib, dasatinib, or ruxolitinib (1 hour). (C) Dose-response curve of Ba/F3 cells after 48 hours’ treatment with JAK3i. Values are normalized to dimethyl sulfoxide controls for each cell line and represent mean ± SD (n = 3). (D) Phosphorylation of STAT5 in Ba/F3 cells at basal levels or after JAK3i treatment (1 hour).

Inhibition of signaling pathways by tyrosine kinase inhibitors in Ba/F3 cells. (A) Ba/F3 cells were treated with dasatinib or ruxolitinib for 1 hour, harvested, and assessed for phosphorylation of STAT5 and CRKL. Heat map indicates mean fluorescent intensity and was generated using Cytobank. (B) Phosphorylation of extracellular signal-regulated kinase 1/2 in Ba/F3-ETV6-NTRK3 cells at basal levels or after treatment with crizotinib, dasatinib, or ruxolitinib (1 hour). (C) Dose-response curve of Ba/F3 cells after 48 hours’ treatment with JAK3i. Values are normalized to dimethyl sulfoxide controls for each cell line and represent mean ± SD (n = 3). (D) Phosphorylation of STAT5 in Ba/F3 cells at basal levels or after JAK3i treatment (1 hour).

Close Modal

or Create an Account

Close Modal
Close Modal